Key result
Cinacalcet fails to reduce cardiovascular events in patients receiving hemodialysis.
Why the study?
The effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis were uncertain.
Does cinacalcet reduce atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis?
Does cinacalcet reduce atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis?
Answers are grounded in this paper and cite their sources.
Cinacalcet may lower CV events in older hemodialysis patients; subgroup analysis leaves open age-specific effects.
Wheeler, David C.; London, Gerard M.; Parfrey, Patrick S.; Block, Geoffrey A.; Correa-Rotter, Ricardo; Dehmel, Bastian; Drueeke, Tilman B.; Flöge, Jürgen; Kubo, Yumi; Mahaffey, Kenneth W.; Goodman, William G.; Moe, Sharon M.; Trotman, Marie-Louise; Abdalla, Safa; Chertow, Glenn M.; Herzog, Charles A.; EValuation Cinacalcet HCl Therapy
No takes yet. Share an insight, caveat, or question.
A 2015 study studied this question. Cinacalcet was evaluated for its effects on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis.
Synapse has enriched 10 related papers. Consider them for comparative context: